Page last updated: 2024-12-11
n-(4-carboxyphenyl)retinamide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
ID Source | ID |
---|---|
PubMed CID | 6505394 |
MeSH ID | M0133149 |
Synonyms (20)
Synonym |
---|
ccris 5521 |
4-(hydroxycarbophenyl)retinamide |
4-carboxyphenylretinamide |
n-(p-carboxyphenyl)retinamide |
sri 7167-67 |
basf 35681 |
retinamide, n-(4-carboxyphenyl)- |
n-(4-carboxyphenyl)retinamide |
74193-17-2 |
unii-qgj09ho5s0 |
qgj09ho5s0 , |
4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoic acid |
DTXSID40225179 |
n-4-carboxyphenylretinamide |
rii-retinamide |
retinamide (rii) |
benzoic acid, 4-((15-oxoretin-15-yl)amino)- |
retinamidic acid |
basf-35681 |
n-4 (car-boxyphenyl) retinamide |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The pharmacokinetic characteristics of RII were studied by HPLC in thirteen cancer patients after oral administration." | ( [Pharmacokinetic study of 4-(hydroxycarbophenyl) retinamide (RII) in cancer patients]. Gu, QM, 1989) | 0.28 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
"Our studies show that the growth of transplantable chondrosarcoma in rats is inhibited significantly by N-4-(hydroxycarbophenyl) retinamide (RII) at a dosage of 50 mg/kg." | ( [Pharmacological studies of N-4-(hydroxycarbophenyl) retinamide]. Han, R, 1991) | 0.28 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (9)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 5 (55.56) | 18.7374 |
1990's | 4 (44.44) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.02
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.02) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (10.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 9 (90.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |